Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Big Brands Poised To Lose US Marketing Exclusivity In 2019

Mar 20 2019

• By Jessica Merrill

closeup of a young caucasian doctor showing a signboard with the text generic drugs written in it

Related Content

Novartis Gives Up On Rituxan Biosimilar For US Market

Nov 05 2018

Generic Sensipar: Cipla Challenges Legality of Amgen/Teva Patent Settlement

Feb 14 2019

Cipla, Piramal Launch Sensipar Generics Amid Growing Antitrust Challenges to Amgen/Teva Settlement

Mar 13 2019

Mylan Clears Runway For US Herceptin Biosimilar Launch

Mar 13 2017

Pfizer: Time To Face The Lyrica Pain

Jan 29 2019

Generic Advair: Finally Approved, A Long Time Coming

Jan 30 2019

Keeping Track: FDA's Review Actions Carry On During Shutdown

Jan 20 2019

Keeping Track: US FDA Receives Submissions Galore As Year Ends

Jan 07 2019

Related Companies

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

GSK plc

Viatris Inc.

Amgen, Inc.

Cipla Limited

Piramal Enterprises Limited

Pfizer Inc.

Allergan plc

Novartis AG

Alkermes plc

Celltrion, Inc.

Samsung Bioepis Co., Ltd.

Novartis AG

Additional Topics

United States Generic Drugs Market Intelligence Legal Issues Commercial BioPharmaceutical

More from Generics

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window